Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

Vir Biotechnology

Status and phase

Terminated

Phase 1

Conditions

Covid19

Treatments

Biological: sotrovimab

Study type

Interventional

Funder types

Industry

Identifiers

NCT05280717

GSK Study 218128 (Other Identifier)

VIR-7831-5012

Details and patient eligibility

About

This clinical pharmacology study will evaluate the relative bioavailability, safety, and tolerability of two different concentrations of sotrovimab injections administered at different injection sites in male or female healthy participants aged 18 to 65 years. The study will be conducted in three parts (Part A, an optional Part B and Part C). Part B and Part C (cohort 2) were optional so they were not initiated. Part C cohort 1 was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes.

Enrollment

316 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or female participants, aged 18 to 65 years, inclusive.
Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
For Part C, inclusion in the Japanese subgroup analysis, a participant must meet all of the following criteria: Japanese ancestry, defined as being a descendant of 4 ethnic Japanese grandparents and 2 ethnic Japanese parents.
Body Mass Index (BMI) within the range of 18 to 30 kilogram per square meter (kg/m^2).
Capable of giving signed informed consent

Exclusion criteria

History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
Breast cancer within the past 10 years
Abnormal blood pressure at Screening.
Known hypersensitivity to any constituent present in the investigational product or history of severe hypersensitivity or anaphylaxis after receiving a COVID-19 vaccine
Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions
Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
Use of any over the counter or prescription medications unless permitted by the protocol or approved by the Investigator in conjunction with the GSK medical monitor.
For Part A and Part B, any condition that would prohibit receipt of injections in the investigator's opinion, such as coagulation disorder, bleeding diathesis, or thrombocytopenia.
Treatment with biologic agents (such as) within 3 months or 5 half-lives
Receipt of convalescent plasma from a recovered COVID-19 participant or anti- severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) monoclonal antibody (mAb) within the last 3 months.
Receipt of any vaccine within 48 hours prior to enrollment.
Has received a SARS-CoV-2 vaccine but has not completed all doses in the series more than 28 days prior to Screening.
Exposure to more than 4 new chemical entities (e.g., investigational pharmaceuticals) within 12 months prior to the first dosing day.
Enrolment in any investigational vaccine study within the last 180 days or enrollment in any other investigational drug study within 30 days prior to Day 1 or within 5 half-lives
Current enrolment or past participation in this clinical study.
A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody test result at Screening or within 3 months prior to dosing.
Positive pre-study drug/alcohol screen.
Positive human immunodeficiency virus (HIV) antibody test.
History of regular alcohol consumption within 6 months prior to the study.
Regular use of known drugs of abuse.
Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

316 participants in 7 patient groups

Part A: Treatment arm 1- Sotrovimab 62.5 mg/mL (Dorsogluteal)

Experimental group

Description:

Participants will receive a single 500 milligram (mg) of 62.5 milligram per milliliter (mg/mL) sotrovimab administered via two injections intramuscularly into the dorsogluteal muscle on Day 1.

Treatment:

Biological: sotrovimab

Part A: Treatment arm 2- Sotrovimab 100 mg/mL (Dorsogluteal)

Experimental group

Description:

Participants will receive a single 500 mg of 100 mg/mL sotrovimab administered intramuscularly into the dorsogluteal muscle on Day 1.

Treatment:

Biological: sotrovimab

Part A: Treatment arm 3- Sotrovimab 100 mg/mL (Anterolateral Thigh)

Experimental group

Description:

Participants will receive a single 500 mg of 100 mg/mL sotrovimab administered intramuscularly into the anterolateral thigh muscles on Day 1.

Treatment:

Biological: sotrovimab

Part A: Treatment arm 4- Sotrovimab 100 mg/mL (Deltoid)

Experimental group

Description:

Participants will receive a single 500 mg of 100 mg/mL sotrovimab administered two injections intramuscularly into the deltoid muscles on Day 1.

Treatment:

Biological: sotrovimab

Part B: Sotrovimab

Experimental group

Description:

Participants will receive 500 mg of 100 mg/mL and/or 62.5 mg/mL sotrovimab on Day 1.

Treatment:

Biological: sotrovimab

Part C: Cohort 1-Sotrovimab

Experimental group

Description:

Participants will receive a single 3000 mg of sotrovimab intravenous (IV) infusion over 60 minutes on Day 1.

Treatment:

Biological: sotrovimab

Part C: Cohort 2-Sotrovimab

Experimental group

Description:

Participants are planned to receive up to 3000 mg of sotrovimab intravenously on Day 1.

Treatment:

Biological: sotrovimab

Trial documents

Trial contacts and locations

Central trial contact

Study Inquiry

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms